The p53 codon 72 polymorphism and association to prostate cancer in Iranian patients

Doosti, Abbas; Dehkordi, Payam Ghasemi

doi:10.5897/ajb11.1442

Cited by 5 publications

(1 citation statement)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, after the careful selection, 22 case–control studies involving 3146 cases and 4010 controls were included in this meta-analysis. [23–44] All these studies were published between 1995 and 2015. Of these, 7 studies were based on Asian, 14 studies based on Caucasian and another 2 studies were based on other races.…”

Section: Resultsmentioning

confidence: 99%

Association between TP53 gene codon72 polymorphism and prostate cancer risk

Han¹,

Cao

Zhang³

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: TP53 gene polymorphism could increase risks of several kinds of cancer. But it remained controversial whether TP53 gene codon72 polymorphism was associated with the susceptibility to prostate cancer. Thus, we conducted a meta-analysis that evaluated the association between TP53 gene codon72 polymorphism and prostate cancer risk. Method: A comprehensive research was performed from PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI) up to December 31, 2018. A random effect model was used to evaluate the effect of the outcome. The statistical analyses were performed with Review Manager 5.3.0 and Stata 14.0. The sensitivity analysis and publication bias tests were also performed to confirm the reliability of this meta-analysis. Results: 22 studies included 3146 cases and 4010 controls were involved in this meta-analysis. Overall, no association was observed between TP53 gene codon72 polymorphism and prostate cancer risk (Arg vs Pro: odds ratio [OR] = 1.12, 95% confidence interval [CI] = 0.98–1.30; ArgArg vs ProPro: OR = 1.26, 95% CI = 0.90–1.75; ProPro vs ArgArg+ ArgPro: OR = 1.17, 95% CI = 0.86–1.57; ArgPro+ ProPro vs ArgArg: OR = 1.21, 95% CI = 0.97–1.51). Subgroup analyses, based on ethnicity, source of control and Hardy–Weinberg equilibrium (HWE) status, showed consistent results. Conclusion: The meta-analysis we performed showed that there was no association of TP53 gene codon72 polymorphism with prostate cancer risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Association between TP53 gene codon72 polymorphism and prostate cancer risk

Han¹,

Cao

Zhang³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta‐analysis

Fan

Hao

Zhang

et al. 2017

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

ObjectiveThe proposal of the present study was to investigate whether the TP53 rs1042522 polymorphism confers susceptibility to prostate cancer (PCa), by performing an updated meta-analysis.MethodsEligible publications investigating the association between the TP53 rs1042522 polymorphism and PCa susceptibility were selected from PubMed, Google Scholar, and Web of Science. We used STATA 12.0 software to conduct the analyses. Odds ratio (OR) with 95% confidence interval (CI) was calculated.ResultsA total of 17 case–control studies were retrieved reporting a total of 2683 cases and 2981 controls. However, no significant association was uncovered between the TP53 rs1042522 polymorphism and PCa susceptibility in the overall population under the five genetic models. In the stratification analysis by source of control, an increased susceptibility to PCa was identified in the population-based (P-B) group (CG vs. GG: OR = 1.48, 95% CI: 1.24–1.77, P < 0.01; CC/CG vs. GG: OR = 1.32, 95% CI: 1.12–1.57, P < 0.01), whereas a decreased susceptibility was uncovered in the hospital-based (H-B) group (CG vs. GG: OR = 0.67, 95% CI: 0.46–0.96, P = 0.03; CC/CG vs. GG: OR = 0.67, 95% CI: 0.46–0.99, P = 0.04) under heterozygous and dominant model.ConclusionThis study did not find an association between the TP53 rs1042522 polymorphism and PCa susceptibility in the overall population and corresponding subgroup analyses except in the stratification analysis by source of control. The results suggest that the TP53 rs1042522 polymorphism is not a risk factor for PCa.

show abstract

Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian population

Toscano-Guerra,

Maggio,

García

et al. 2024

Preprint

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common cancer in men and the third leading cause of cancer death in Europe. TheTP53gene, the most frequently mutated gene in human cancer, is a tumor suppressor gene with crucial functions in preventing tumor development. The single nucleotide polymorphism rs1042522, characterized by the substitution of a proline (PRO) for an arginine (ARG) at the position 72 of the p53 protein (P72R SNP), was studied in 12 primary tumor cultures from prostate biopsies of untreated hormone-naïve patients (hnPCs) with aggressive-metastatic cancer (Gleason ≥8), 11 radical prostatectomies, and a cohort of 94 serums from patient with aggressive prostate cancer using DNA sequencing and melting curve analysis. The results identified a high frequency of the P72R SNP in prostate cancer samples compared to the general European (non-cancer) population, suggesting a very significant association (p<0.0001) between this SNP and the risk of prostate cancer with an odds ratio of 7.937 (IC 95% 5.37-11.00). The G allele (R72) was more frequent in patients with high Gleason scores (≥8) suggesting its association to more undifferentiated-malignant PCa lesions.

show abstract

The p53 codon 72 polymorphism and association to prostate cancer in Iranian patients

Cited by 5 publications

References 16 publications

Association between TP53 gene codon72 polymorphism and prostate cancer risk

Association between TP53 gene codon72 polymorphism and prostate cancer risk

Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta‐analysis

Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian population

Contact Info

Product

Resources

About